ArticleFundamental research2026
Disruption of the nucleocapsid-RNA condensation by punicalagin is a broad-spectrum antiviral approach.
Article in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking the Therapeutic Potential of Ellagitannins: A Comprehensive Review of Key Representatives.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The formation of liquid condensates by nucleocapsid (N) protein and viral RNA is a critical and highly conserved event in the life cycle of numerous viruses. Targeting this process emerges as a possible strategy to combat viral infections. Here, we discover that punicalagin, a natural compound derived from Punica granatum, exhibits potent pan-antiviral activity. Through a screening of 2799 compounds, we identified that punicalagin inhibits the formation of N-RNA condensations at nanomolar concentrations, resulting in significant inhibition of viral replication. The oral administration of punicalagin effectively dampens the viral load in tissues of mice infected with various viruses, such as SARS-CoV-2, vesicular stomatitis virus (VSV) and influenza A virus (IAV). Moreover, we show that punicalagin also blocks the virus-stimulated inflammation by targeting mitochondrial antiviral signaling protein (MAVS), thereby alleviating tissue damage and lethality in the infected animals. Thus, by reporting that punicalagin targets the conserved process across different viruses, our work suggests a new paradigm for developing antiviral therapies against both current and future viral threats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.